[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [HEALTH]

2 clusters · 5 sources · 1 days · First seen · Last updated

Medical research in metabolic and liver diseases

Overview

Medical research has identified new potential pathways for treating metabolic diseases, specifically focusing on liver health and obesity.

Researchers at Cedars-Sinai have identified the UBE2N enzyme as a potential target for metabolic dysfunction-associated steatohepatitis (MASH). Studies indicate that UBE2N levels decline as liver disease progresses from MASLD to MASH. The enzyme appears to protect the liver by facilitating mitophagy, a process where damaged mitochondria are cleared. When UBE2N is deficient, the protein p62 accumulates incorrectly, contributing to inflammation, fat accumulation, and scarring.

In parallel, advancements in obesity treatment have been reported through the phase III SYNCHRONIZE-1 clinical trial. Results published in the New England Journal of Medicine highlight the experimental drug Survodutide, developed by Boehringer Ingelheim and Zealand Pharma. As a dual agonist for GLP-1 and glucagon receptors, Survodutide aims to reduce appetite and influence metabolism differently than first-generation GLP-1 agonists.

Entities

Cedars-Sinai · UBE2N · Boehringer Ingelheim · Nature Metabolism · Zealand Pharma

Timeline

  1. [HEALTH] 3 sources
    Medical research advances in liver disease and obesity treatments

    New research explores the role of the UBE2N enzyme in preventing liver fibrosis and examines Survodutide, an experimental dual agonist drug for obesity and metabolic regulation.

  2. [HEALTH] 2 sources
    UBE2N enzyme identified as potential target for MASH liver disease

    A Cedars-Sinai study identifies the UBE2N enzyme as a potential target for treating MASH, showing that restoring enzyme levels in mice reduces liver inflammation, fat, and scarring.

Sources

farmacoecura.it · it-boltwise.de · microbiologiaitalia.it · senseaboutscience.org.uk · vanityfair.it